Prosecution Insights
Last updated: October 01, 2026

Examiner: XIE, XIAOZHEN

Tech Center 1600 • Art Units: 1646 1674

This examiner grants 57% of resolved cases

Analysis

Xiaozhen Xie is an examiner in Art Unit 1646 of Tech Center 1600. He has 696 resolved cases and an allowance rate of 56.6%. The median days to allowance is 1311, which reflects a lengthy and detailed examination process. These metrics suggest a balanced environment where success requires persistence and clear technical differentiation. Practitioners should plan for a timeline that exceeds three and a half years on average.

The interview lift is 65.8%. This is one of the highest lift figures, suggesting that interviews are the single most important factor in securing an allowance with this examiner. Practitioners should prioritize interviews early in the prosecution process to overcome the 56.6% baseline allowance rate. The 696 resolved cases provide a strong statistical foundation for these observations. Given the 1311-day median to allowance, utilizing the 65.8% lift is a critical tactical choice. Overall, the data points to a process where direct communication is highly rewarded and can significantly improve the probability of a grant.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

56.6%
Allow Rate
-3.4% vs TC avg
708
Total Applications
+65.8%
Interview Lift
1311
Avg Prosecution Days
Based on 696 resolved cases, 2023–2026

Rejection Statute Breakdown

3.4%
§101 Eligibility
20.2%
§102 Novelty
31.1%
§103 Obviousness
32.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17615959 ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS Non-Final OA Janssen Biotech, Inc.
17470455 BIOMARKERS AND METHODS FOR ASSESSING PSORIATIC ARTHRITIS DISEASE ACTIVITY Non-Final OA The Regents of the University of California
17432177 LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION Final Rejection Rutgers, the State University of New Jersey
18248280 TREATMENT OF FLARES IN LUPUS Final Rejection ASTRAZENECA AB
17419932 TEST METHOD FOR ULCERATIVE COLITIS AND PRIMARY SCLEROSING CHOLANGITIS Non-Final OA KYOTO UNIVERSITY
18577206 SYSTEMS AND METHODS FOR DELIVERY BASED ON SUPRAMOLECULAR NANOSTRUCTURES Non-Final OA Children's Medical Center Corporation

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month